Morgan Stanley Maintains Overweight on PAE, Lowers Price Target to $11.5

Morgan Stanley analyst Matthew Sharpe maintains PAE (NASDAQ:PAE) with a Overweight and lowers the price target from $12 to $11.5.

byBenzinga Newsdesk

June 15, 2021

1 minute read

Morgan Stanley analyst Matthew Sharpe maintains PAE (NASDAQ:PAE) with a Overweight and lowers the price target from $12 to $11.5.

Freshpet Q2 EPS $(0.45) Misses $(0.14) Estimate, Sales $146.01M Miss $147.03M Estimate

By Benzinga Newsdesk

Today, 10:37 PM

Freshpet (NASDAQ:FRPT) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.14) by 221.43 percent. This is a 164.71 percent decrease over losses of $(0.17) per share from the

FRPT

What Is Going On With Clover Health Stock?

By Shivdeep Dhaliwal

Today, 10:37 PM

Clover Health Investments Corp (NASDAQ: CLOV) spiked more than 13% on Wednesday in the regular session. What Happened: Clover Health stock shot up on a day when the so-called Stonks, or stocks favored by the retail investor crowd on social media, took the limelight.

AMC

Elon Musk’s SpaceX Seeks Higher Valuation In $1.7B Funding Round Amid Sexual Harassment Allegations

By Rachit Vats

Today, 10:37 PM

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk-owned SpaceX is looking to raise $1.725 billion in new capital that could lift the private space firm's valuation to $127 billion, CNBC

TSLA

News

aTyr Pharma And FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement For aTyr’s Lead Therapeutic Candidate ATYR1923

By Benzinga Newsdesk

Today, 10:37 PM

aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract

LIFE

Morgan Stanley Maintains Overweight on PAE, Lowers Price Target to $11.5

Related Posts

Freshpet Q2 EPS $(0.45) Misses $(0.14) Estimate, Sales $146.01M Miss $147.03M Estimate

What Is Going On With Clover Health Stock?

Elon Musk’s SpaceX Seeks Higher Valuation In $1.7B Funding Round Amid Sexual Harassment Allegations

aTyr Pharma And FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement For aTyr’s Lead Therapeutic Candidate ATYR1923